- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05604508
Testing Legally Feasible Options Studies 2/3
January 3, 2025 updated by: William Shadel, RAND
Testing Legally Feasible Options at Retail Point of Sale - Prices and Posters
The overall aim of this research is to experimentally evaluate different, legally-viable approaches to reducing the impact of the point-of-sale (POS) retail environment on adolescent tobacco use risk.
This study will be investigating regulations for four classes of tobacco products (cigarettes, e-cigarettes, smokeless tobacco, little cigars/cigarillos).
Study 2 and study 3 (out of 3 studies), occurring concurrently, will examine whether changing the number and content of posters on the outside doors at POS reduced adolescents' tobacco use risk.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Tobacco advertising at retail point-of-sale (POS) includes promotional allowances that permit tobacco products to be advertised and sold at reduced cost to consumers (e.g., two-for-one specials); high visibility sale and therefore placement of hundreds of tobacco products on power walls; and the display of a large, diverse collection of poster advertisements on the exterior of the stores.
Adolescents are at significant risk for having repeated exposures to this tobacco rich POS environment and such exposures contribute to increases in adolescent tobacco use.
Although curbing the effect of the tobacco rich POS environment on adolescent tobacco use is a critical public health goal, some POS advertising regulations are unlikely to be viable in the United States because they impinge upon the tobacco industry's commercial free speech rights.
For example, eliminating the tobacco power wall is probably not a viable option in the US as it has been successfully challenged in court by the tobacco industry.
POS regulations that do not violate the industry's commercial free speech rights stand a better chance of being upheld by the courts.
For example, eliminating tobacco product price promotions, reducing the availability of tobacco products by restricting the sale of flavored products, and restricting how much door/window space tobacco product posters can occupy at POS, all have been implemented as feasible and legally defensible regulatory options at POS.
The evidence base supporting the efficacy of these initiatives is, however, almost non-existent - leaving them open to legal scrutiny.
The overall aim of this research is to experimentally evaluate different, legally-viable approaches to reducing the impact of the POS retail environment on adolescent tobacco use risk.
This research will be investigating the regulations for four classes of tobacco products (cigarettes, e-cigarettes, smokeless tobacco, little cigars/cigarillos): the extent to which eliminating tobacco product price promotions (Study 2), restricting how much door/window space tobacco posters can occupy at POS (Study 3), and eliminating the sale of flavored and/or mentholated tobacco products (Study 1) reduce adolescent tobacco-use risk.
Each study will evaluate for possible gender and race (African-American vs Caucasian) differences.
The studies will take place in the RAND StoreLab, a life-sized replica of a convenience store that was developed to experimentally evaluate how altering aspects of tobacco promotion at POS influences tobacco use.
The present record is for Study 2 and Study 3.
Study Type
Interventional
Enrollment (Actual)
445
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- RAND Corporation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 20 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
ages 18-20, in college
-
Exclusion Criteria:
any medical or psychiatric condition which would make compliance with the study protocol difficult (based on parent report).
Previous participation in a previous StoreLab study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Status Quo
This condition will allow for many posters with pricing information to be displayed.
|
No poster number or price restrictions
|
|
Experimental: Reduced Poster
This condition will allow for a reduced number of posters with pricing information to be displayed.
|
Poster number restrictions, but no price restrictions
|
|
Experimental: No price
This condition will allow for many posters with no pricing information to be displayed.
|
No poster number restrictions, but price restrictions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported Cigarette Smoking Risk After Shopping in the StoreLab
Time Frame: There is one visit in this research: This variable is assessed at that visit, within 5 minutes of the experimental manipulation
|
Respondents answer the following items: "Do you think you will try a cigarette anytime soon?", "Do you think you will try a cigarette anytime in the next year?";
and "If one of your best friends offered you a cigarette, would you smoke it?".
Responses are made on a 1 (Definitely not) to 10 (Definitely yes) scale and summed to produce a total smoking risk scale score (range from 3 - 30).
Total scale scores are dichotomized: scores of 3 are coded as '0' (no risk) and any score greater than 3 is coded as '1' (at risk).
Outcome is proportion at risk of cigarette smoking (number of participants at risk over number of participants within condition).
|
There is one visit in this research: This variable is assessed at that visit, within 5 minutes of the experimental manipulation
|
|
Self-reported Vaping/ENDS Risk of Use
Time Frame: There is one visit in this research: This variable is assessed at that visit, within 5 minutes after experimental manipulation
|
Respondents answer the following items: "Do you think you will try a vaping product anytime soon?", "Do you think you will try a vaping product anytime in the next year?";
and "If one of your best friends offered you a vaping product, would you use it?".
Responses are made on a 1 (Definitely not) to 10 (Definitely yes) scale and summed to produce a total vaping risk scale score (range from 3 - 30).
Total scale scores are dichotomized: scores of 3 are coded as '0' (no risk) and any score greater than 3 is coded as '1' (at risk).
Outcome is proportion at risk of vaping (number of participants at risk over number of participants within condition).
|
There is one visit in this research: This variable is assessed at that visit, within 5 minutes after experimental manipulation
|
|
Self-reported Smokeless Tobacco Use Risk
Time Frame: There is one visit in this research: This variable is assessed at that visit, within 5 minutes of the experimental manipulation
|
Respondents answer the following items: "Do you think you will use smokeless tobacco anytime soon?", "Do you think you will try smokeless tobacco anytime in the next year?";
and "If one of your best friends offered you smokeless tobacco, would you use it?".
Responses are made on a 1 (Definitely not) to 4 (Definitely yes) scale and summed to produce a total smokeless tobacco risk scale score (range from 3 - 30).
Total scale scores are dichotomized: scores of 3 are coded as '0' (no risk) and any score greater than 3 is coded as '1' (at risk).
Outcome is proportion at risk of smokeless tobacco use (number of participants at risk over number of participants within condition).
|
There is one visit in this research: This variable is assessed at that visit, within 5 minutes of the experimental manipulation
|
|
Self-reported Cigarillo/Little Cigar *LCC) Use Risk
Time Frame: There is one visit in this research: This variable is assessed at that visit, within 5 minutes of the experimental manipulation
|
Respondents answer the following items: "Do you think you will try a cigarillo/little cigar anytime soon?", "Do you think you will try a cigarillo anytime in the next year?";
and "If one of your best friends offered you a cigarillo, would you smoke it?".
Responses are made on a 1 (Definitely not) to 4 (Definitely yes) scale and summed to produce a total cigarillo risk scale score (range from 3 - 30).
Total scale scores are dichotomized: scores of 3 are coded as '0' (no risk) and any score greater than 3 is coded as '1' (at risk).
Outcome is proportion at risk of LCC use (number of participants at risk over number of participants within condition).
|
There is one visit in this research: This variable is assessed at that visit, within 5 minutes of the experimental manipulation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 12, 2022
Primary Completion (Actual)
March 7, 2024
Study Completion (Actual)
March 7, 2024
Study Registration Dates
First Submitted
October 28, 2022
First Submitted That Met QC Criteria
October 28, 2022
First Posted (Actual)
November 3, 2022
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 3, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- R01CA236608studies23
- R01CA236608 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
Loma Linda UniversityUniversity of California, San Francisco; Riverside University Health System...RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in ChildbirthUnited States
-
University of Mississippi Medical CenterNot yet recruitingTobacco Cessation
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco AbstinenceUnited States
-
University of FloridaRecruitingTobacco Use | Nicotine UseUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Duke UniversityCompletedSmokeless Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedTobacco Product Beliefs and UseUnited States
Clinical Trials on Many posters with prices
-
Ankara Yildirim Beyazıt UniversityRecruitingCongenital Heart Disease in AdolescenceTurkey
-
University of TorontoThe CIHR Social Research Centre in HIV PreventionCompleted
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Indiana UniversityCompletedMetastatic Breast CancerUnited States